Yunnan Baiyao

Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows

A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021

On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.

Yunnan Baiyao: An Oriental Mystery in the Limelight (2/2)

Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.

Yunnan Baiyao: An Oriental Mystery in the Limelight (1/2)

Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.